


Poly-D,L-Lactide-co-Glycolide-co-pseudo-L-Z-Serine Ester (PLGpZS)



Poly-D,L-Lactide-co-Glycolide-co-pseudo-L-Serine Ester (PLGpS)

FIG. 1

2 / 36




FIG.2

3/36




FIG.3

4 / 36




FIG.4A




FIG.4B

5/36
Differential Number




FIG.4C





FIG.4D


6(a)/36

FIG.5A



PLGpZS encapsulating PBS


FIG.5B



PLGpS encapsulating PBS


FIG.6A

6(b)/36



PLGpZS encapsulating Antigen

FIG.6B



PLGpS encapsulating Antigen

7 / 36




FIG. 7A

8 / 36




FIG. 7B

Anti-Hin-47 IgG Antibody Responses
from PLG, PLGpZS and PLGpS Microspheres
(Day 10, 24, 35, 45 and 60)
Subcutaneous Immunizations (Day 1 and 35)




FIG.8A

Anti-Hin-47 IgG Antibody Responses
from Physical Mixes of PLG/PBS Microspheres
and Hin-47 (Day 10, 24, 35, 45 and 60)
Subcutaneous Immunizations (Day 1 and 35)




FIG. 8B

Anti-Hin-47 IgG Subtypes
 Low Dose Groups (Day 35 and 60)
 Subcutaneous Immunizations (Day 1 and 35)




FIG.8C




FIG. 9A




FIG. 9B

14 / 36

Anti-Hin-47 IgA Antibody Responses
 From Sera (Day 78)
 Oral Immunizations (Day 1, 7, 14 and 57)




FIG. 9C




FIG. 10A




FIG. 10B

17 / 36




FIG. 10C

18 / 36

Anti-Hin-47 IgD Antibody Responses
From Lung Lavage (Day 78)
Intranasal Immunizations (Day 1, 7, 14 and 57)




FIG. 10D

19 / 36

Anti-Hin-47 IgA Antibody Responses
 From Lung Lavage (Day 78)
 Intranasal Immunizations (Day 1, 7, 14 and 57)




FIG. 10E

Anti-Flu X-31 IgG Antibody Responses
from PLG, PLGpZS and PLGpS Microspheres
(Day 21 and 33)
Subcutaneous Immunization (Day 1)




FIG. 11

21/36




FIG. 12

22 / 36

HAI titres from Sera (Day 21, 42 and 57)
 Subcutaneous Immunization (single dose)
 PLGpS/Flu (A-Texas) and BAY R1-005 Formulations
 Dose - Flu = 10 µg, HA = 3.50 µg

7
 6
 5
 4
 3
 2
 1
 0

Avg log 2 HAI titres/15

■ Day 21
 ■ Day 42
 □ Day 57




FIG. 13

Anti-Flu (A/Texas) IgG Antibody Responses
 Single Dose - Subcutaneous Study
 PLGpS Microparticles and Flu (trivalent) Formulations
 (Day 21, 42 and 57)




FIG. 14A

Anti-Flu (A/Johannesburg) IgG Antibody Responses
 Single Dose-Subcutaneous Study
 PLGpS Microparticles and Flu (trivalent) Formulations
 (Day 21, 42 and 57)




FIG. 14B

25 / 36

Anti-flu (B/Harbin) IgG Antibody Responses
 Single Dose-Subcutaneous Study
 PLGpS Microparticles and Flu (trivalent) Formulations
 (Day 21, 42 and 57)




FIG. 14C

HAI titres (A/Texas) from Sera (Day 21, 42 and 57)
 Subcutaneous Immunization (single dose)
 PLGpS Microparticles and Flu (trivalent) Formulations
 Low Dose - Flu = 10 µg, Total HA = 2.35 µg
 High Dose - Flu = 21.2 µg, Total HA = 5.00 µg




FIG. 15A

HAI titres (A/Johannesburg) from Sera (Day 21, 42 and 57)
 Subcutaneous Immunization (single dose)
 PLGpS Microparticles and Flu (trivalent) Formulations
 Low Dose - Flu = 10 µg, Total HA = 2.35 µg
 High Dose - Flu = 21.2 µg, Total HA = 5.00 µg




FIG. 15B

28/36

HAI titres (B/Harbin) from Sera (Day 21, 42 and 57)
 Subcutaneous Immunization (single dose)
 PLGpS Microparticles and Flu (trivalent) Formulations
 Low Dose - Flu = 10 µg, Total HA = 2.35 µg
 High Dose - Flu = 21.2 µg, Total HA = 5.00 µg




FIG. 15C

Weight Loss Study on Mice Immunized Subcutaneously (Single Dose) with PLGpS Microparticles and Flu Trivalent (10 ug -2.35 ug total HA) Vaccine Formulations Challenged With (A/Taiwan) Virus

29 / 36




FIG. 16

30/36




FIG. 17A

31 / 36

Anti-Tbp2 IgG Subtype Responses (Day 55)
Subcutaneous Immunizations (Day 1, 28 and 43)




FIG. 17B

32 / 36




FIG. 18

33 / 36




FIG. 19




FIG.20

35 / 36

Protection Study - Challenge with *H. Pylori* (Day 85) on Mice Immunized Subcutaneously with PLGpS/rUrease Microparticle Formulations




FIG.21A

Protection Study - Challenge with *H. Pylori* (Day 85) on Mice Immunized Orally with
PLGpS/rUrease Microparticle Formulations




FIG.21B